Wells Fargo downgraded Inozyme (INZY) to Equal Weight from Overweight with a $4 price target after BioMarin Pharmaceutical (BMRN) announced a definitive agreement to acquire the company for $4.00 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Inozyme Pharma’s INZ-701 Shows Promising Results in ENERGY-3 Study, Highlighting Investment Potential
- BioMarin says Inozyme deal to strengthen enzyme therapies portfolio
- Inozyme downgraded to Neutral from Outperform at Wedbush
- Inozyme Pharma Merges with BioMarin for $270 Million
- BioMarin’s acquisition of Inozyme to strengthen enzyme therapies portfolio